Circassia Pharmaceuticals PLC’s (CIR) “Hold” Rating Reiterated at Peel Hunt

Peel Hunt restated their hold rating on shares of Circassia Pharmaceuticals PLC (LON:CIR) in a research note released on Tuesday morning. They currently have a GBX 130 ($1.72) price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on CIR. J P Morgan Chase & Co lowered their target price on Circassia Pharmaceuticals PLC from GBX 120 ($1.58) to GBX 110 ($1.45) and set a neutral rating for the company in a report on Thursday, September 28th. Numis Securities Ltd restated a buy rating and issued a GBX 180 ($2.38) price objective on shares of Circassia Pharmaceuticals PLC in a report on Wednesday, September 27th.

TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at

Circassia Pharmaceuticals PLC Company Profile

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.

What are top analysts saying about Circassia Pharmaceuticals PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Circassia Pharmaceuticals PLC and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit